Skip to content
Isavuconazonium
Cresemba (isavuconazonium) is a small molecule pharmaceutical. Isavuconazonium was first approved as Cresemba on 2015-03-06.
Download report
Favorite
Commercial
Therapeutic Areas
No data
Trade Name
FDA
EMA
Cresemba
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Isavuconazonium sulfate
Tradename
Company
Number
Date
Products
CRESEMBAAstellas PharmaN-207500 RX2015-03-06
2 products, RLD, RS
CRESEMBAAstellas PharmaN-207501 RX2015-03-06
1 products, RLD, RS
Labels
FDA
EMA
Brand Name
Status
Last Update
cresembaNew Drug Application2019-12-02
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
Expiration
Code
ISAVUCONAZONIUM SULFATE, CRESEMBA, ASTELLAS
2027-03-06GAIN
2025-03-06GAIN
2022-03-06ODE*, ODE-305, ODE-90
2020-03-06NCE
Patent Expiration
Patent
Expires
Flag
FDA Information
Isavuconazonium Sulfate, Cresemba, Astellas
102068792027-09-14DP
106032802027-09-14DP
68122382025-10-31DP
108122382025-10-31DP
ATC Codes
J: Antiinfectives for systemic use
J02: Antimycotics for systemic use
J02A: Antimycotics for systemic use
J02AC: Triazole and tetrazole derivatives
J02AC05: Isavuconazole
HCPCS
Code
Description
J1833
Injection, isavuconazonium, 1 mg
Clinical
Clinical Trials
89 clinical trials
View more details
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Iron-deficiency anemiaD018798HP_0001891D5035126832
AnemiaD000740EFO_0004272D64.928127329
Chronic renal insufficiencyD051436N182619
Iron deficienciesD000090463E61.113138
Heart failureD006333EFO_0003144I50122216
Chronic kidney failureD007676EFO_0003884N18.6134
Inflammatory bowel diseasesD015212EFO_00037671113
Altitude sicknessD000532EFO_1000782T70.29112
Hip fracturesD006620EFO_0003964S72.0022
Renal dialysisD006435EFO_0010690Z99.211
Show 5 more
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Renal insufficiencyD051437HP_0000083N191213
NeoplasmsD009369C80112
Hematologic neoplasmsD019337111
LeukemiaD007938C9511
LymphomaD008223C85.911
Plasma cell neoplasmsD05421911
Non-hodgkin lymphomaD008228C85.911
Multiple myelomaD009101C90.011
B-cell chronic lymphocytic leukemiaD015451C91.111
Weight lossD015431HP_000182411
Show 2 more
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Wounds and injuriesD014947T14.8112
Pulmonary hypertensionD006976EFO_0001361I27.20112
Replacement arthroplasty kneeD01964511
Chronic diseaseD00290811
Ovarian epithelial carcinomaD000077216111
Kidney diseasesD007674EFO_0003086N0811
Heart diseasesD006331EFO_0003777I51.9111
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Healthy volunteers/patients33
Therapeutic equivalencyD01381011
Indications Without Phase
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Lung neoplasmsD008175C34.9011
Premature birthD047928EFO_0003917O6011
PregnancyD011247EFO_0002950Z33.111
Critical illnessD01663811
Heart disease risk factorsD00008274211
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameISAVUCONAZONIUM
INNisavuconazonium chloride
Description
Isavuconazole is a 1,3-thiazole that is butan-2-ol which is substituted at positions 1, 2, and 3 by 1,2,4-triazol-1-yl, 2,5-difluorophenyl, and 4-(p-cyanophenyl)-1,3-thiazol-2-yl groups, respectively. It is an antifungal drug used for the treatment of invasive aspergillosis and invasive mucormycosis. It has a role as an ergosterol biosynthesis inhibitor, an EC 1.14.13.70 (sterol 14alpha-demethylase) inhibitor and an orphan drug. It is a member of 1,3-thiazoles, a nitrile, a difluorobenzene, a tertiary alcohol, a triazole antifungal drug and a conazole antifungal drug.
Classification
Small molecule
Drug classquaternary ammonium derivatives; quaternary ammonium derivatives
Image (chem structure or protein)
Structure (InChI/SMILES or Protein Sequence)
CNCC(=O)OCc1cccnc1N(C)C(=O)OC(C)[n+]1cnn(C[C@](O)(c2cc(F)ccc2F)[C@@H](C)c2nc(-c3ccc(C#N)cc3)cs2)c1
Identifiers
PDB
CAS-ID241479-67-4
RxCUI1720882
ChEMBL IDCHEMBL1183349
ChEBI ID85978
PubChem CID6918485
DrugBankDB11633
UNII IDHZQ5R80I6Y (ChemIDplus, GSRS)
Target
Agency Approved
No data
Alternate
No data
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Additional graphs summarizing 401 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
3,397 adverse events reported
View more details